DENTSPLY SIRONA heads into its June 2 earnings report with short sellers unusually active — and the stock down sharply over the past month.
Short interest has become the dominant story. It has climbed to 12.6% of free float, up nearly 20% in a single week and 24% over the past month — a notably aggressive build ahead of a scheduled catalyst. The ORTEX short score has risen in step, reaching 58.1 from around 53 two weeks ago, confirming the trend is accelerating rather than plateauing. Yet the borrow market isn't stretched: availability is running at roughly 551% of short interest, well above the tightest levels seen over the past year, and cost to borrow remains low at 0.58% — rising but not yet signaling any squeeze pressure.
Options traders, however, are telling a different story. The put/call ratio has dropped to 0.63, more than a standard deviation below its 20-day average of 0.78, pointing to a tilt toward calls rather than puts heading into the print. That diverges sharply from the short interest build — short sellers are piling in while options flow leans bullish. The stock closed at $10.47, down 11% over the past month, but has clawed back about 2.5% over the past week, suggesting at least some near-term stabilisation.
The analyst community captures the debate well. The consensus is a hold, with 11 analysts on the sidelines and just two at outperform. UBS and Mizuho both trimmed price targets in early May while keeping their ratings intact — a sign the Street sees limited near-term catalysts but hasn't given up on the turnaround thesis. Citigroup initiated with a Sell in mid-April, setting a $10 target that sits almost exactly at the current price. Bulls point to early signs of operational improvement in the US business, the elimination of the dividend to fund debt reduction, and a forward EPS growth estimate that ranks in the top third of the universe. Bears counter with persistent executive turnover — the CFO departure being the most recent example — a reduced FY26 profit outlook, and a turnaround that, after several iterations of restructuring, has yet to visibly land. At 7x trailing earnings and an EV/EBITDA of 6.8x, the valuation offers a margin of safety, but the discount reflects genuine uncertainty rather than an overlooked opportunity.
Institutional positioning adds a constructive wrinkle. Southpoint Capital and Vanguard entities each initiated or significantly increased positions as of end-March, and BlackRock added half a million shares through April. In March, Chairman Greg Lucier bought 15,000 shares in the open market at around $12.45 — above where the stock trades today. That cluster of buying from board level and active managers contrasts with the recent short build, and sets up a meaningful tension heading into the print: the June 2 report is less a test of whether the business is recovering and more a test of whether the pace of recovery is fast enough to satisfy an increasingly impatient short side.
See the live data behind this article on ORTEX.
Open XRAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
